Cvrx, Inc. key statistics and ratios
In fiscal 2025, Cvrx, Inc. had return on equity of -96.6%, an operating margin of -90.5%, debt equal to 127.1% of equity and a current ratio of 7.63. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Gross margin | 76.2% | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% | 86.9% |
| Operating margin | −190.2% | −199.2% | −189.3% | −109.7% | −116.0% | −90.5% | −79.5% |
| Net margin | −233.1% | −330.5% | −184.4% | −104.8% | −116.9% | −94.1% | −84.9% |
| Free-cash-flow margin | −271.1% | −221.8% | −193.0% | −100.8% | −79.0% | −71.9% | −67.1% |
| Return on equity | — | — | −32.5% | −44.5% | −81.6% | −96.6% | −175.3% |
| Return on assets | −21.8% | −39.6% | −29.9% | −34.3% | −48.2% | −44.8% | −52.7% |
| Asset turnover | 0.09 | 0.12 | 0.16 | 0.33 | 0.41 | 0.48 | 0.62 |
| Current ratio | 8.07 | 25.57 | 15.19 | 14.25 | 12.06 | 7.63 | 8.04 |
| Debt to equity | — | 0.0% | 6.2% | 39.5% | 70.4% | 127.1% | 300.7% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 105.9% | 57.5% | 44.3% | 29.6% | 21.7% | 19.7% | 20.2% |
| SG&A as % of revenue | 160.5% | 213.7% | 222.7% | 164.2% | 178.0% | 156.2% | 146.2% |
| Capital spending as % of revenue | 5.1% | 9.1% | 3.0% | 1.5% | 2.7% | 1.0% | 1.0% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 83.2% | 83.2% | 83.5% | 84.3% | 86.8% | 86.3% | 87.2% | 87.4% |
| Operating margin | −97.3% | −67.0% | −108.8% | −105.8% | −83.5% | −69.8% | −82.3% | −82.9% |
| Net margin | −98.0% | −69.4% | −111.5% | −108.4% | −87.6% | −74.5% | −88.8% | −89.4% |
| Free-cash-flow margin | −78.1% | −52.5% | −104.3% | −59.2% | −68.1% | −61.3% | −83.2% | −56.9% |
| Current ratio | 11.32 | 12.06 | 14.83 | 11.99 | 9.62 | 7.63 | 10.20 | 8.04 |
| Debt to equity | 75.5% | 69.3% | 71.1% | 85.3% | 102.9% | 125.9% | 200.9% | 293.5% |
| R&D as % of revenue | 18.7% | 18.3% | 20.4% | 18.2% | 21.4% | 18.7% | 20.9% | 19.9% |
| SG&A as % of revenue | 161.8% | 131.9% | 171.9% | 171.9% | 148.9% | 137.4% | 148.7% | 150.4% |
Financial health
- Short-term assets cover short-term liabilities $89m of assets due within a year against $11m of liabilities due within a year.
- Short-term assets cover long-term liabilities $89m short-term assets against $61m of longer-dated liabilities.
- More cash than debt $65m of cash against $59m of debt.
- Debt below 40% of shareholders' equity Debt is 294% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 0% to 294% over five years.
- A year's operating cash flow covers at least 20% of debt −$40m of operating cash flow against $59m of debt.
- Operating profit covers interest at least five times over Operating income of −$49m against $6m of interest.
Moat
Weak moat
How hard Cvrx's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -35.7% of total assets over 5 years.
- Pricing power 17 / 20
Gross margin has been a median 82.5%, moving by 5.0 percentage points (standard deviation) across 6 years.
- Durability 10 / 20
Operating margin has been a median -136.2%; its worst year was -229.0%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 6 years, at a median -117.1% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Alpha PRO Tech LTD statistics
- Lensar, Inc. statistics
- Apyx Medical Corp statistics
- Iridex Corp statistics
- Electromed, Inc. statistics
Head to head: APT vs CVRXCVRX vs LNSRAPYX vs CVRX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies